BOCA RATON, Florida, March 16, 2016 /PRNewswire/ --

Vycor Medical, Inc. ("Vycor") (OTCQB-VYCO), a provider of innovative and superior surgical and therapeutic solutions, announced that it has launched the VBASMini, the smallest and most minimally invasive model in its range of ViewSite Brain Access System devices.

The VBASMini was developed in close collaboration with a leading neurosurgeon who had identified a need to develop a much smaller VBAS than those currently available to allow for less invasive surgery yet still enable the use of instruments. The VBASMini is the largest clear device available that can fit through a burr hole yet still provides a large enough working channel to be useful in neurosurgery, and was designed to overcome the limitations of carrying out work through the likes of an endoscopic sheath. The smaller size also enables minimally invasive approaches to areas where existing retractors are too potentially invasive, such as the ventricles. The VBASMini comes in two lengths and is half the diameter of Vycor's current smallest VBAS device and is now available for purchase.

The VBASMini can retrieve a larger specimen than through a conventional neuro-endoscope and can be used to remove intracerebral hematomas, drain abscess, remove an intra-ventricular tumor and allow for outflow of irrigation while using endoscope and instruments and the placement of catheters and shunts.

Dr. George Magram, who recently retired as the Medical Director of Neurosurgery of Valley Children's Hospital, Madera CA, and who worked with Vycor to develop the VBASMini, commented: "Having worked with Vycor during the design stage and viewed the final devices, I believe they will greatly improve endoscopic intra-ventricular work such as the placement of catheters and shunts or gaining access to ventricular tumors. I also believe the minimally invasive profile of these smaller devices will be particularly useful for pediatric ventricular work. As the next generation of neurosurgeons get experienced with the VBAS, they will be able to take advantage of the endoscope, microscope, the new exoscope, and custom made instruments for use with VBASMini, furthering the goal of minimizing the invasiveness of neurosurgery."

Peter Zachariou, Vycor's Chief Executive Officer, commented, "We believe that the launch of the VBASMini represents an exciting opportunity for Vycor to address under-served neurosurgical needs in the market and is consistent with our stated objective of adding new product extensions to our core VBAS product line. The limitations provided by current alternatives is the reason behind the design and development of the VBASMini. We feel confident that as surgeons try the device and familiarize themselves with it they will see that it offers far greater features than might appear at first sight. Given the VBASMini's extremely small dimensions and smooth shape, we believe the models represent a significant step forward in minimally invasive retraction and access. We believe the VBASMini will help address an estimated additional 25,000 procedures in the US which were previously un-addressable by Vycor's existing VBAS product range."

About Vycor Medical, Inc. 

Vycor Medical (OTCQB: VYCO) is dedicated to providing the medical community with innovative and superior surgical and therapeutic solutions. The company has a portfolio of FDA cleared medical solutions that are changing and improving lives every day. The company operates two business units: Vycor Medical and NovaVision, both of which adopt a minimally or non-invasive approach.

Vycor Medical's ViewSite™ Surgical Access Systems (VBAS) is a suite of clear cylindrical minimally invasive disposable devices that hold the potential for speedier, safer and more economical brain surgeries and a quicker patient discharge. VBAS is designed to optimize neurosurgical site access, reduce patient risk, accelerate recovery and add tangible value to the professional medical community. The company is ISO 13485:2003 compliant, has U.S. FDA 510(k) clearance for brain and spine surgeries and regulatory approvals for brain in Australia, Brazil, Canada, China, Europe (EU - Class III), Korea, Japan, Russia and Taiwan. For an overview of Vycor Medical's VBAS, see VBAS Video.

NovaVision provides non-invasive, computer-based rehabilitation targeted at a substantial and largely un-addressed market of people who have lost their sight as a result of stroke, or brain injury.

NovaVision's family of therapies both restore and compensate for lost vision. NovaVision's VRT is the only medical device aimed at the restoration of vision lost as a result of neurological damage which has FDA 510(k) clearance to be marketed in the U.S. NeuroEyeCoach is a compensation therapy registered in the US as a Class I 510(k) exempt device, VRT and NeuroEyeCoach are highly complementary and provided to patients in an Internet-delivered suite, to ensure broad benefits to patients. For an overview of NovaVision see NovaVision Video.

For the latest information on the company, including media and other coverage, and to learn more, visit http://www.vycormedical.com, http://www.vycorvbas.com or http://www.novavision.com.    

Vycor Medical, Inc Contacts: 

6401 Congress Avenue
Suite 140
Boca Raton, FL. 33487

+1-(561)558-2020
info@vycormedical.com

SOURCE Vycor Medical, Inc.